SEC Form 4 · accession 0001209191-19-006858
GYRE THERAPEUTICS, INC. · GYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Fletcher Payne
Officer — Chief Financial Officer
Period of report
Feb 4, 2019
Accepted (ET)
Feb 4, 2019 · 4:52 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001124105
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 4, 2019 | M | 1,503 | $4.63 | A | 3,230 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.63 | Feb 4, 2019 | M | 1,503 | D | — | Jul 11, 2027 | Common Stock | 1,503 | 73,497 | D |
Explanation of responses
- F1The Option vests monthly over a period of four years commencing June 15, 2017.